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Introduction
Endemic throughout Latin America
with a prevalence rate of approximately
1.4%, Chagas disease (CD) is estimated to
kill 14,000 people every year, which is
more people in the region each year than
any other parasite-born disease, including
malaria [1,2]. Brazilian physician Carlos
Chagas first described CD exactly a
century ago [3], and its socioeconomic
impact makes it the most important
parasitic disease in the Americas [4].
Estimated to infect somewhere between 8
to 14 million people, CD both afflicts the
poor and, like other neglected tropical
diseases, ‘‘promotes poverty’’ [2,5].
Through its impact on worker productiv-
ity, and by causing premature disability
and death, CD annually costs an estimated
667,000 disability-adjusted life years lost
[1,6]. In the case of Brazil alone, losses of
over US$1.3 billion in wages and indus-
trial productivity were due to the disabil-
ities of workers with CD [7].
CD is an important public health issue,
both in Latin America and increasingly
around the world: the infection rate in
endemic areas is estimated to be 1.4% [8],
with geographic variation from 0.1% to
45.2% [9]. Vectorial transmission has
been significantly reduced due to control
efforts like the Southern Cone Initiative
[10,11] and others [11,12]. However,
there are areas producing new cases such
as regions untouched by vector control
efforts [13], special areas with non-domi-
ciliated triatomine [14], and the Amazon
region with recent cases reported via oral
transmission and by wild triatomine [15].
And still to this day, millions of patients
remain without adequate treatment for
this silently debilitating and potentially
fatal disease. Although no official global
figures exist, it is estimated that no more
than 1% of those infected are believed to
receive any treatment at all. An increasing
number of CD patients are also seen in
non-endemic, developed countries because
of globalization and the movement of
unknowingly infected people from Latin
America to other parts of the world
[16,17,18]. The appearance of Trypanoso-
ma cruzi in blood banks in the United
States has led the Food and Drug
Administration (FDA) to recently issue a
draft guidance on CD screening [19].
The Need for New, Improved
Treatments
To better understand the need for new
treatments, it is important to review a bit
of CD pathology and clinical evolution.
Caused by infection with the protozoan
parasite T. cruzi, CD starts with an acute
phase in which the parasitemia is often
high and parasitological diagnosis can be
made by direct microscopic examination
of fresh blood. This disease phase (in
which 2%–8% of children die) [20,21]
frequently passes undiagnosed in the
absence of active screening programs, as
CD manifests itself with a febrile and
toxemic illness having non-specific symp-
toms reminiscent of any childhood infec-
tion. If untreated, the disease transitions
into a clinically silent, indeterminate
chronic phase. Later, 10 to 30 years after
the initial infection, approximately 30% of
infected people will experience the symp-
tomatic, chronic stage characterized by
severe organ pathologies primarily involv-
ing the cardiac and gastrointestinal sys-
tems [22,23]. During the long-lasting
chronic phase, parasites are primarily in
the tissues, thereby rendering direct para-
sitological diagnosis difficult or impossible.
At this stage, diagnosis is based on serology
and more recently on molecular diagnosis
via polymerase chain reaction (PCR).
Hemoculture and xenodiagnosis can also
be done, but with limited sensitivity.
Current treatment is limited to only two
drugs: nifurtimox (Lampit; Bayer) and
benznidazole (LAFEPE-BENZNIDA-
ZOLE, Laboratorio Farmace ˆutico do
Estado de Pernambuco [LAFEPE]). Un-
fortunately, these drugs are limited to the
treatment of children with acute infection
and early chronic disease (,12 years old)
[24], with growing evidence for treatment
in indeterminate disease [25,26,27]. For
the chronic phase with target organ
involvement, few studies support their
use as parasitological therapy [27,28],
but the BENEFIT trial supported by the
Special Programme for Research and
Training in Tropical Diseases (TDR) is
expected to fill this knowledge gap [29].
Even in children, who are known to better
tolerate treatment with these nitroheter-
ocyclic compounds than adults, the cure
rate for chronic indeterminate cases is up
to 62% at 2 year follow-up [24,25,30], and
it may vary according to population and
geographical location [25,26,27,31]. Both
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period that fosters a high rate of patient
non-compliance, and dose- and time-
dependent toxicity is also seen [32]. No
pediatric strength or formulation is avail-
able for benznidazole (Figure 1); a 30-mg
tablet strength of nifurtimox was devel-
oped and registered, but is not currently
available. Because of the poverty and
remoteness of the primary target popula-
tion, guaranteeing access to diagnosis and
treatment is a challenge.
Although new, improved treatments
against CD are urgently needed, no new
anti-CD drugs are in clinical development,
and only one class of drugs, the antifungal
triazoles, have demonstrated potential for
therapeutic switching. While some prom-
ising academic and non-commercial drug
discovery efforts exist, the current drug
research and development (R&D) pipeline
is still very limited, with no new drug
expected within the next 3–4 years.
Barriers to Development and
Evaluation of Treatments
A lot of research has been conducted on
the parasite T. cruzi over the past century,
culminating in the sequencing of its
genome and proteome in 2005 [33,34].
However, basic research on T. cruzi has yet
to translate into new therapeutic tools for
CD for a number of reasons.
In early stage research, many com-
pounds might show promising activity
against T. cruzi, but there is little stan-
dardization among the protocols or para-
sites used for each assay. Reproducibility
has sometimes been difficult across labo-
ratories; several so-called active com-
pounds have been identified using assays
not relevant to disease pathology (i.e.,
screening against parasitic epimastigotes
and trypomastigotes) and many screening
labs do not have (1) capacity/expertise to
run assays with a reasonable throughput
due to the nature of the T. cruzi assay, (2)
pharmaceutical knowledge to conduct
drug development on their hits, or (3)
collaborations with partners having this
knowledge (work stops after publication of
results).
Few rigorous clinical trials have been
conducted in CD [24,26,28]. For years,
one of the important challenges in drug
development for CD has been the evalu-
ation of drug efficacy in the population
representing the highest disease burden,
patients with chronic indeterminate CD.
Such patients do not present any clinical
disease manifestation, and serological test-
ing may remain positive for 5 years or
even longer after treatment. To date, there
are no randomized clinical trials evaluat-
ing the impact of treatment at the
indeterminate phase of disease as it evolves
into chronic cardiac or gastrointestinal
disease. Since these manifestations occur
in ,30% of patients over 10–30 years
after infection, such clinical trials would
require very large sample sizes and
decades of follow-up, and are therefore
practically unfeasible. These concerns
have contributed significantly to the pau-
city of new drugs that have been clinically
assessed as CD treatments—clinical re-
search is simply deemed ‘‘too difficult’’.
Hence, new research tools in designing
clinical trials and surrogate markers of
cure are needed.
Responding to the Need—
Promising Developments with
New Partnerships
Difficult challenges lie ahead in the
quest for the elimination of CD, as was
acknowledged by the World Health Or-
ganization (WHO) in its recent report to
the World Health Assembly [35], even as
several new initiatives emerge on both the
control and the research landscape.
One such development is the creation of
non-profit product development partner-
ships (PDPs) working to fill the gaps in
essential health tools for neglected diseases
[36]. These emergent PDPs offer a
valuable alternative model, as R&D is no
longer financed by a product’s sale price.
In the case of CD, the Drugs for Neglected
Diseases initiative (DNDi), a PDP, is
currently working to build a well-balanced
and robust CD-specific portfolio that
urgently addresses the needs of CD
patients. Improved treatments and re-
search tools are required—DNDi aims to
deliver an effective, non-toxic, inexpensive
treatment proven effective for the acute,
indeterminate, and chronic phases of CD.
Work is also ongoing to develop a
pediatric formulation of benznidazole, as
this could represent a great improvement
in point-of-care case management.
The changes seen in the past decade
offer a new landscape in which to
collaborate and to advance improved
treatments for neglected diseases like CD,
but, to ensure that these efforts are
sustained and strengthened, greater invest-
ments (complemented with new and
adapted funding mechanisms) are needed
from both governments and the private
sector. DNDi continues to identify and
engage partners, so as to ensure that a
well-balanced pipeline is established for
CD, one of its three diseases of primary
focus.
Figure 1. Fractionation of benznidazole tablets. At a health post in Honduras, benznidazole
tablets are fractionated by hand into K and J tablets. Fractionation of tablets is not ideal, as
there is a high risk of delivering the improper dosage, thereby raising concerns about safety,
efficacy, and decreased stability. (Photo courtesy of the National Chagas and Leishmaniasis
Control Program of Honduras.)
doi:10.1371/journal.pntd.0000484.g001
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Matching needs and opportunities,
DNDi’s portfolio is a mix of projects in-
sourced at any stage of the development
process, from early discovery through
post-registration, with the objective to
bring new, field-relevant tools to patients
in the shortest time and most efficient way
possible. Preclinical and clinical develop-
ment activities are streamlined and fo-
cused on the ultimate goal: a new
treatment that reaches patients and con-
tributes to improved disease control.
TheCD-specificportfoliobalancesshort-
and long-term objectives. In the short and
mid-term,theaimisforbetteruseofexisting
treatments through new formulations, ther-
apeutic switching, and combination thera-
py. In the long term, new chemical entities
must be developed. Another important
element in DNDi’s strategy for CD is to
address the methodological constraints that
impact the design of clinical studies.
In order to best meet research oppor-
tunities and most immediately address
patient needs, DNDi utilizes a target
product profile (TPP). As a hypothetical
‘‘package insert’’, the TPP contains ele-
ments that describe the ideal product to
guide the development process. Table 1
gives an overview of the ideal and
minimally acceptable TPP for chronic
indeterminate CD.
A number of research activities hold
promise at various stages throughout the
pipeline, although it is clear that more
research is needed (Figure 2). The high
attrition rate of the pipeline is well
known—even in late stages, only one in
every five drugs that enter clinical trials
becomes available to patients [37].
Highlighted below are some of DNDi’s
key activities along with some promising
work being done elsewhere at institutions
like Fiocruz, the University of California,
San Francisco (UCSF), and the University
of Washington. These activities are divid-
ed below by how long the development
time will roughly take.
Long-Term Projects (.6 Years)
Drug discovery. Some of the
promising targets in T. cruzi include
protein prenylation, hypoxanthine-
guanine phosphoribosyltransferase,
cysteine proteases [38,39],
topoisomerases [40], 14-demethylase
inhibitors [41,42], squalene synthase
inhibitors [43], farnesyl pyrophosphate
synthase inhibitors [44], farnesyl
transferase inhibitors [45,46],
dihydrofolate reductase inhibitors [47],
and natural products like canthinones,
quinolines, naphthoquinones, and lignans
[48,49,50].
Much of these data must still be
confirmed by additional laboratories: key
elements in DNDi’s drug discovery process
include (1) accessing broad chemical
diversity through a number of different
sources and partnerships such as a natural
products screening network and collabo-
rations with pharmaceutical companies,
(2) ensuring standard operating procedures
in place for in vitro and in vivo assays to
ensure that screening at different sites and
with different groups are comparable, and
(3) increasing screening capacity for CD.
An important challenge for the screen-
ing of new compounds is the limited
output of currently available screening
methodologies. In a partnership at the
forefront of technology development,
DNDi and Institute Pasteur Korea are
working to develop a visual-based high-
throughput screening platform for T. cruzi.
High-throughput screening offers the pos-
sibility of more rapid hit identification to
be progressed as drug candidates.
Lead optimization (screening to
drug candidate). In 2008, a lead
optimization consortium was set up by
DNDi for CD so as to engage in a critical,
iterative process that helps to optimize the
efficacy of a lead compound while
minimizing its toxicity. This consortium
includes institutions in Australia (Monash
and Murdoch Universities and Epichem)
and Brazil (Universidade Federal de Ouro
Preto) and consists of a group of analytical
and medicinal chemists, pharmacologists,
Table 1. Target Product Profile for Developing a Treatment for Chronic Indeterminate Phase of CD.
Acceptable Ideal
Target label Early chronic/indeterminate CD Early chronic/indeterminate CD + Reactivations
(Immunocompromised)
T. cruzi sub-species TcI+TcII TcI+TcII
Distribution All areas All areas
Target population Immunocompetent Immunocompetent + Immunocompromised
Adult/children Adult All
Clinical efficacy Superiority over benznidazole in all endemic regions (parasitological) 70% (parasitological and serological)
.95% cure for reactivated patients (parasitological and serological)
Resistance Active against nitrofuran- and nitroimidazole-resistant T. cruzi strains Active against nitrofuran- and nitroimidazole-resistant T. cruzi strains
Safety Superiority to benznidazole Superiority to benznidazole
3 clinical evaluations plus 2 standard laboratory evaluations during
treatment
No monitoring needed during treatment
Contraindications Pregnancy/lactation None
Precautions No genotoxicity; no prolongation of QTc interval No genotoxicity; no teratogenicity; no negative inotropic effect; no
prolongation of QTc interval
Interactions No clinically significant interaction with anti-hypertensive,
anti-arrythmic, or anticoagulants drugs
None
Presentation Oral Oral
Stability 3 years, climatic zone IV 5 years, climatic zone IV
Dosing regimen Comparable to systemic antifungal treatments Two times a day for 60 days
doi:10.1371/journal.pntd.0000484.t001
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facilities or compound assessment.
Medium-Term Projects (3–6 Years)
Therapeutic switching. With the
high attrition of early screening and lead
optimization efforts, a key approach in
minimizing the risks and length of drug
R&D time is to evaluate compounds
registered or in clinical development for
other indications with demonstrated in
vitro and/or in vivo activity in CD. A
potential target for therapeutic switching is
ergosterol biosynthesis, a pathway
effectively targeted for antifungal therapy
that shares considerable similarity with the
trypanosome pathway. However, most of
the clinically employed sterol biosynthesis
inhibitors (such as ketoconazole and
itraconazole) are not able to induce
complete parasitological cure in human
Chagas disease and animal models [51].
A new generation of antifungal triazoles
including posaconazole, voriconazole, and
ravuconazole, show considerable promise
as anti-trypanosomal agents. The market-
ed antifungal drug posaconazole (Noxafil,
Schering-Plough) has previously been
shown to induce parasitological cure in
mice with acute and chronic infections,
including benznidazole-resistant strains
[48,52]. It is considered the leading azole
candidate for proof-of-concept evaluation.
Two other triazole derivatives, ravucona-
zole (Eisai) and TAK-187 (Takeda), have
shown encouraging in vitro and in vivo
results [53,54]. Both products have com-
pleted Phase I testing and are good
candidates for further assessment as po-
tential CD treatments.
Combination treatment. A main
limitation to the broader use of
etiological treatment in CD is the poor
tolerability reported with currently
available treatments. Side effects of
benznidazole and nifurtimox are both
time- and dose-dependent [48].
Combination therapy could improve
treatment efficacy; could reduce dosage,
treatment duration, and toxicity; and
could also prevent the potential
development of parasitic resistance to
currently available treatments. Azole
derivatives have shown synergistic anti–
T. cruzi effects, in vitro and in vivo, with
benznidazole and other compounds
involved in the sterol biosynthesis
pathway [42]. Taking these results into
consideration, DNDi has begun preclinical
studies with the objective of reducing the
dose and duration of current CD
treatments by systematically evaluating
these two drugs in combination with
azole compounds.
Short-Term Projects (,3 Years)
Reformulation. Since the 1990s,
there has been consensus for the early
diagnosis and treatment of children and
adolescents in the early indeterminate
(chronic) phase of CD. Young children
remain an important target population for
treatment despite decreasing vectorial
transmission, because congenital infection
may remain an important mode of
transmission for at least another
generation. This is not reflected in the
current treatment options, as current
Figure 2. Ongoing drug R&D projects on Chagas disease. There are a few promising projects at early-stage discovery and clinical stages;
however, the high attrition rate of the pipeline means that only one in ten compounds will be progressed from discovery into preclinical testing; and
in late stages, only one in every five drugs that enter clinical trials becomes available to patients. Success rate based on estimates from Nwaka et al.
2003 [37].
doi:10.1371/journal.pntd.0000484.g002
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that is, not adapted to children’s weights.
Tablet fractionation (Figure 1) and
extemporaneous formulations are needed
to treat most children; these procedures
increase the likelihood of improper
dosages and raise safety concerns,
particularly in the very young and
malnourished, as well as concerns about
reduced efficacy (due to the addition of
diluents) and stability.
A number of approaches have been
examined to best meet the need of
developing a new pediatric formulation
that is affordable, age-adapted, and easy to
comply with: an improved solution at the
Universidad Nacional de Rosario Argen-
tina and an adapted, dispersible tablet
through a collaboration between LAFEPE
and DNDi. Signed in July 2008, this
collaboration seeks to develop and file for
registration a dispersible pediatric tablet
for the treatment of CD in endemic
countries by the end of 2010.
Clinical Research—Tackling the
Challenges
Outside of specific drug development
projects, DNDi is working to address a
number of issues that could make clinical
research ‘‘less difficult’’: (1) Methodolog-
ical issues for proof-of-concept eval-
uation in CD—the long period for
seroconversion after parasite elimination
in CD presents an important challenge in
the evaluation of etiological treatment. In
recent years, an increasing body of data
has pointed to a strong biological rationale
for the use of parasitological outcomes as
surrogate markers of therapeutic response
in CD. A TDR-sponsored study for the
standardization and validation of qualita-
tive PCR testing for T. cruzi has just been
completed, which represents a valuable
first step for future clinical trials. Further
work is still needed for validation of
quantitative PCR and better definition of
procedures for employment in drug stud-
ies. (2) Clinical site identification—
clinical trial sites must be identified that
will ensure adequate recruitment of pa-
tients with different stages of the disease
and who are infected with different strains
of T. cruzi. (3) Clinical research
strengthening platform for CD—the
Chagas Platform is being formed in 2009
with various partners to strengthen clinical
research capacities by developing a critical
mass of expertise, strengthening institu-
tional research capacity, and supporting
an environment conducive to quality
research in order to review and facilitate
the registration and recommendation of
new therapies for CD.
Conclusion
One century after the discovery by
Chagas, progress has been made along
the path to understanding and controlling
CD; however, much remains to be done in
order to truly be able to adequately treat
this disease afflicting a reported 9.8 million
patients [55]. The unmet medical needs of
patients remain great, given the limitations
of current drugs. Progress has been too
little and too limited, with a small
spectrum of chemical classes currently
available as antitrypanosomal drugs or
identified as druggable compounds. More
activity and partnership is needed in order
to increase access to adequate and
better-adapted diagnosis and treat-
ment.
Rooted in partnerships with all sectors
and focused on patient needs, PDPs have
shown that needs-driven innovation pro-
viding patients in resource-poor settings
with important therapeutic improvements
can be efficiently delivered, as seen with a
number of improved malaria medicines
[56]. As of 2004, 75% of active drug
development projects for neglected diseas-
es were conducted by PDPs, with eight to
nine new drugs expected in the market by
2010 [57]. However, PDPs alone cannot
meet the urgent needs of neglected
patients.
Funding for R&D to improve treat-
ments for CD is strikingly low, given the
100 million people at risk and CD’s
disease burden. Less than US$1 million
(only 0.04% of R&D funding dedicated to
neglected diseases) was spent on the
development of new drugs for CD in
2007 [58]. For a disease extending its
global fingers and for which no treatment
exists for the chronic stage, the time to
develop improved treatments is now.
Through growing opportunities to act
synergistically, public and private sectors
must work together to make available a
better treatment and tools for CD.
The increasing level of attention paid to
CD in the new millennium offers reason
for hope; greater efforts have been made
to control CD, regional and worldwide
research networks are being strengthened
and built, and pharmaceutical companies
have begun to share their libraries for
neglected diseases. However, an opportu-
nity was lost at this year’s World Health
Assembly when CD, at the 100th anni-
versary of its discovery, was dropped from
the agenda due to concerns about a
potential flu pandemic. A disease that
continues to debilitate and kill people
every day deserves to have more attention
paid to it so that true innovation can be
delivered to the patients in need of
adequate treatments. Visit http://www.
treatchagas.org to join the campaign.
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